-
Oct. 29, 2021
Roivant Discovery Announces 2021 Open Science Fellows
Drs. Gregory Bowman, Alex Dickson and Paul Robustelli selected as fellows due to shared focus on understanding the structures and dynamics of biological systems at atomic resolution. NEW YORK and BOSTON, Oct. 29, 2021 – Roivant Discovery, the drug discovery engine for Roivant Sciences (Nasdaq: ROIV), today announced that Dr. Gregory R. Bowman, Dr. Alex Dickson and Dr. Paul…
-
Oct. 1, 2021
Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing
Roivant will begin trading on Nasdaq under the ticker “ROIV” later today R&D Day presentations from September 28th highlighting Roivant’s pipeline and discovery platform available on Roivant’s investor page BASEL, LONDON, NEW YORK, and BOSTON, Oct. 1, 2021 – Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that…
-
Feb. 26, 2021
Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics
Leading computational physics-based platform for design and optimization of small molecules bolsters Roivant’s drug discovery capabilities Silicon Therapeutics drug discovery executives Dr. Woody Sherman, Dr. Huafeng Xu, and Dr. Chris Winter to join Roivant leadership; Drs. Sherman and Xu are industry pioneers in computationally powered drug discovery Physics-based approaches at Silicon Therapeutics to be integrated…
